International and multidisciplinary features are the most important mission of IASLC. As an active IASLC board member, I will make every effort to achieve the above specific mission. I will help IASLC to prepare more educational sessions and regional workshops on different continents. I will help IASLC to organize and launch more global multi-center clinical trials. I will accelerate educational programs in various formats including webinars, podcasts, network platforms, and a virtual library of meeting content. I will increase the local exchanges and collaboration among different countries and attract more members from various countries, regions, and backgrounds. More importantly, to keep the feature of diversity of IASLC. At the same time, bringing together clinicians and researchers can both educate and foster communication on scientific and clinical advances. I will focus on member experience and the interactions with scientific projects, education and continuing medical education (CME), patient advocacy, and publications. I will strengthen multidisciplinary cooperation and research, prevention, and treatment, integrating the wisdom of thoracic surgeons, medical oncologists, pathologists, radiologists, pulmonologists, pharmacists, scientists, bioinformatics, and artificial intelligence specialists, et al., to accelerate the pace of thoracic malignancy research worldwide, including focusing on patients with rare mutations and rare thoracic malignancy. In this scenario, IASLC can help build criteria for lung cancer precision diagnosis and therapy. IASLC should be involved in rapid integration of molecular biomarkers into clinical practice and be the leader in defining international standards and guidelines for molecular testing, staging and early detection & screening, and patient management.